Skip to main content
Premium Trial:

Request an Annual Quote

PEOPLE: GenomeWeb s Weekly Personnel Roundup in the Genomics Sector: Oct 17, 2001

NEW YORK, Oct. 17 – Deltagen has appointed Jeanne Y. Jew as vice president of business development, the company said on Wednesday. She was also made a member of the firm's executive management committee.

“We are actively looking at drug candidates internally and externally and I am confident Ms. Jew will provide tremendous value to our expanded business development efforts," said William Matthews, president and CEO of the genomic-based biotechnology company.

Before joining Deltagen, based of Redwood City, Calif., Jew was vice president of business development at Corixa where she directed new business-development activities and managed research collaborations and partnerships.


Digital Gene Technologies has named Kevin T. Skol as vice president of business development, the company announced on Oct. 17.  

Skol will be responsible for new business-development opportunities, including forming new collaborations, overseeing existing partnerships, and working to increase DGT's industry exposure, DGT said in a statement.

Before coming to DGT, which is based in La Jolla, Calif., Skol served in the New York-based business development group at Elan, where he helped direct US business-development activities specializing in drug-development and drug-delivery partnerships between Elan and a wide range of US biotech and biopharmaceutical companies.  


Structural Genomix has hired Stephen K. Burley to be chief scientific officer and senior vice president of R&D, the company said on Oct. 16. He will start in January 2002.

Burley will be responsible for directing all R&D activities for the San Diego-based company. He also will advise the SGX board and management on the firm’s scientific vision.

Burley is currently deputy for Academic Affairs at The Rockefeller University, where he holds the Richard M. and Isabel P. Furlaud Professorship and directs the Pels Family Center for Biochemistry and Structural Biology. He also is a Full Investigator with the Howard Hughes Medical Institute and serves as the Principal Investigator of the New York Structural Genomics Research Consortium.


Variagenics  has named  Jay Mohr vice president of business development and marketing, the company announced on Oct. 16. The firm has also hired John Frey to be senior director for regulatory affairs and clinical informatics, a newly established position.

Mohr will oversee Variagenics’ marketing and business-development teams while managing worldwide strategic partnership collaborations within the biopharmaceutical and pharmaceutical industries, the company said.

Frey, meanwhile, will head the company's regulatory affairs, biostatistics, and clinical information sciences functions. He will also serve as the company's corporate privacy officer, ensuring ethical privacy and confidentiality protection for participants in Variagenics ' R&D programs.

Before joining Variagenics , of Cambridge, Mass., Mohr served as executive vice president of Serono's Metabolic Endocrinology Strategic Business Unit. Frey comes to Variagenics with experience in R&D, biostatistics, new-product development, clinical, scientific, and regulatory affairs for a variety of pharmaceutical, CRO, and medical device companies.


Perceptive Informatics has appointed Jay B. Zimmerman as vice president of operations of medical diagnostics, where he will oversee the company’s medical imaging business operations, Perceptive said on Oct. 16

Zimmerman comes to Boston-based Perceptive from EndPoint Imaging Solutions, where he was president, COO, and co-founder. Before his stint at EIS, he was vice president of clinical operations at Photogen.


Ingenium Pharmaceuticals has hired to serve on its supervisory board Erich Platzer , chairman of Novuspharma and former Therapeutic Area Head of Oncology Global Strategic Marketing at F. Hoffmann La Roche, and Richard Aldrich , former senior vice president and chief business officer of Vertex Pharmaceuticals, Ingenium said on Oct. 15.

“The appointments will help Ingenium to expand and exploit its global leadership in Deductive Genomics … and to develop as a drug discovery company in its own right,” the company said in a statement.

Platzer is a board-certified hematologist and medical oncologist who worked with a team of scientists at Memorial Sloan-Kettering Cancer Center in New York to purify initially natural human G-CSF, which ultimately led Amgen to develop the cancer blockbuster Neupogen.

Aldrich most recently served as senior vice president and chief business officer at Vertex, where he was responsible for business development, finance, marketing, corporate communications, and operations.

Ingenium is headquartered in Martinsried, Germany.


Millennium Pharmaceuticals has hired Allan Marchington as senior vice president of productivity, the firm said on Oct. 11.

His new position is a promotion from his previous post as general manager of Millennium Pharmaceuticals, Millennium's European division.

Marchington will report directly to CEO Mark Levin and will be responsible for the company's overall productivity initiative that includes reducing product-development cycle times, identifying more effective technology integration and work processes, and maximizing the use of knowledge and information to accelerate drug commercialization, according to a statement.  

Marchington succeeds Susan Ward , who has undertaken a new advisory role assisting Levin, the company said.

Millennium is located in Cambridge, Mass.


Toronto-based Ellipsis has appointed Ronald Cape as chairman of the board, the company announced on Oct. 10.

Cape co-founded Cetus in 1971, where he oversaw the development of polymerase chain reaction, and interleukin-2 and beta-interferon. He headed Cetus from its founding until it merged with Chiron in 1991.

Later, Cape co-founded Darwin Molecular Corporation. He now serves on the boards of a number of biotechnology companies.


Applied Biosystems has named Lauren M. Linton vice president of applications marketing and R&D in the firm’s Applications and Products Organization, the company said on Oct. 10.

Linton will have responsibility for R&D and marketing for instruments and consumables product families made by the Foster City, Calif.-based company. She will report to Stephen J. Lombardi, vice president of applications and products.

Linton comes to Applied Biosystems, which is a unit of Applera, from the Whitehead Institute at the Massachusetts Institute of Technology, where she was associate director of the Center for Genome Research and co-director with Eric Lander of the Genome Sequencing Center there.


Louis A. Matis , president of Cellular Genomics , has also been named CEO of the company, and Mark Velleca has been promoted to vice president of research.

Matis joined Cellular Genomics in September 2000 as president and chief scientific officer. Before joining the firm, he served for eight years at Alexion Pharmaceuticals, where he most recently was senior vice president and chief scientific officer.

Velleca, a senior director of research at Cellular Genomics, is a founding scientist of the company and has led its R&D programs since it began operations. He came to Cellular Genomics, based in Branford, Conn., from Yale Medical School, where continues to hold an adjunct appointment as clinical assistant professor of laboratory medicine.


Promoted? Changing jobs?  GenomeWeb wants to know. Help us keep track of you by e-mailing us at [email protected] PEOPLE , a roundup of personnel comings and goings in genomics, appears each Wednesday.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.